Source: Visiopharm/Neagen

News • Digital pathology

New Technical Integration between image analysis and PACS

Neagen and Visiopharm announce an integration which improves the data quality of cancer patient samples in a single PACS-driven digital pathology workflow also offering time and cost savings. This in term enhances quality for pathologists working in cancer research and diagnostics and benefits the patients.

Visiopharm is a worldwide leader of Augmented Pathology within tissue research and diagnostics and Neagen offers a true vendor neutral enterprise imaging system based on worldwide DICOM standard.

“We are excited to see an increased demand for both workflow automation and improved interpretive accuracy from pathologists in Finland. These are the two areas where Visiopharm makes a real difference. By integrating our Augmented Pathology software with neaLink, customers can now integrate precision pathology into PACS-driven workflows, to achieve better data quality, turnaround times, and reduce manual labor”, says Michael Grunkin, CEO Visiopharm.

Photo
Source: Visiopharm/Neagen

“Neagen sees digital pathology as indispensable in the modern pathology lab, and seamless integration into other existing diagnostic medical workflows is a pivotal requirement to successful deployment. neaLink VNA is a modern and scalable enterprise imaging solution for all medical disciplines. With this technical integration, our customers across the globe will be able to combine advanced image analysis to digital pathology with radiology in a seamlessly integrated digital workflow, to further enhance neaLink as a platform for integrated diagnostics”, says Lasse Jyrkinen, CEO Neagen.

The Oncotopix solution is compatible with and validated for all major scanner formats, and has been validated and CE-marked for the three major reagent vendors. Making Oncotopix available as a simple and seamlessly integrated plug-in to PACS and LIS systems, makes it possible to deploy and scale digital pathology in the lab, one cost-efficient and risk-free step at a time.


Source: Visiopharm/Neagen

05.09.2017

Read all latest stories

Related articles

Photo

Sponsored • Automated DIA

Use the digital image analysis in Breast Cancer

In a study of 436 breast cancer cases with 28 years of survival data histo-pathologists from Karolinska Institute, Stockholm, Sweden shows that protein tissue-based biomarker data are at least as…

Photo

Article • Immuno-oncological biomarkers

Seeking to augment the value of tumour infiltrating lymphocytes

Measuring tumour infiltrating lymphocytes (TILs) is gaining importance in immunotherapy, but other variables must also be considered to boost prognosis and prediction accuracy, a leading pathologist…

Photo

Article • Updating laboratories

Digital pathology gains a foothold in Hungary

Hungary has one of the worst outcomes when it comes to cancer. Early detection and accurate diagnosis could significantly reduce the costs of oncological treatment. Pathology plays a crucial role in…

Related products

CliniSys | MIPS – DaVinci

Information Technology

CliniSys | MIPS – DaVinci

CliniSys | MIPS Deutschland GmbH
Mesalvo – LabCentre

LIS, Middleware, POCT

Mesalvo – LabCentre

Mesalvo Mannheim GmbH (ehemals i-SOLUTIONS Health GmbH)
Agfa HealthCare – Dose Monitoring System

Dose Management Systems

Agfa HealthCare – Dose Monitoring System

Agfa HealthCare
Agfa HealthCare – Enterprise Imaging Platform

Mobile RIS/PACS Viewer

Agfa HealthCare – Enterprise Imaging Platform

Agfa HealthCare
Subscribe to Newsletter